Profile of palbociclib in the treatment of metastatic breast cancer

References

• FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2014161253525524798
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalAAmerican Cancer SocietyCancer Facts & Figures 2015AtlantaAmerican Cancer Society2015651529
   Google Scholar
• WeigeltBGeyerFCReis-FilhoJSHistological types of breast cancer: how special are they?Mol Oncol20104319220820452298
   PubMed Web of Science ®Google Scholar
• de RuijterTCVeeckJde HoonJPJvan EngelandMTjan-HeijnenVCCharacteristics of triple-negative breast cancerJ Cancer Res Clin Oncol2011137218319221069385
   PubMed Web of Science ®Google Scholar
• MatsumotoAJinnoHAndoTBiological markers of invasive breast cancerJpn J Clin Oncol20154hyv153
   Web of Science ®Google Scholar
• Darb-EsfahaniSLoiblSMüllerBMIdentification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyBreast Cancer Res2009115R6919758440
   PubMed Web of Science ®Google Scholar
• MasoodSBreast cancer subtypes: morphologic and biologic characterizationWomens Health (Lond Engl)201612110311926756229
   PubMedGoogle Scholar
• American Cancer SocietyBreast Cancer Facts & Figures 2015–2016AtlantaAmerican Cancer Society Inc2015
   Google Scholar
• AlmstedtKSchmidtMTargeted therapies overcoming endocrine resistance in hormone receptor-positive breast cancerBreast Care201510316817226557821
   PubMed Web of Science ®Google Scholar
• McClendonAKDeanJLRivadeneiraDBCDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapyCell Cycle201211142747275522751436
   PubMed Web of Science ®Google Scholar
• LuJSteegPSPriceJEBreast cancer metastasis: challenges and opportunitiesCancer Res200969124951495319470768
   PubMedGoogle Scholar
• ElbazMNasserMWRaviJModulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancerMol Oncol20159490691925660577
   PubMed Web of Science ®Google Scholar
• ManginiNSWesolowskiRRamaswamyBLustbergMBBergerMJPalbociclib: a novel cyclin-dependent kinase inhibitor for hormone receptor-positive advanced breast cancerAnn Pharmacother201549111252126026324355
   PubMed Web of Science ®Google Scholar
• O’SullivanCCOvercoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 InhibitorsInt J cancer Clin Res201524
   PubMedGoogle Scholar
• HudisCAGianniLTriple-negative breast cancer: an unmet medical needOncologist201116suppl 111121278435
   PubMed Web of Science ®Google Scholar
• LawsonDABhaktaNRKessenbrockKSingle-cell analysis reveals a stem-cell program in human metastatic breast cancer cellsNature2015526757113113526416748
   PubMed Web of Science ®Google Scholar
• BeaverJAAmiri-KordestaniLCharlabRFDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancerClin Cancer Res201521214760476626324739
   PubMed Web of Science ®Google Scholar
• RingADowsettMMechanisms of tamoxifen resistanceEndocr Relat Cancer200411464365815613444
   PubMed Web of Science ®Google Scholar
• Yamamoto-ibusukiMArnedosMAndréFTargeted therapies for ER +/HER2- metastatic breast cancerBMC Med20151313726059247
   PubMed Web of Science ®Google Scholar
• MayerELTargeting breast cancer with CDK inhibitorsCurr Oncol Rep201517544325716100
   PubMed Web of Science ®Google Scholar
• NagarajGMaCRevisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancerBreast Cancer Res Treat2015150223124225762475
   PubMed Web of Science ®Google Scholar
• HosfordSRMillerTWClinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathwaysPharmgenomics Pers Med2014720321525206307
   PubMedGoogle Scholar
• HayashiSKimuraMMechanisms of hormonal therapy resistance in breast cancerInt J Clin Oncol201520226226725652907
   PubMed Web of Science ®Google Scholar
• MalumbresMBarbacidMTo cycle or not to cycle: a critical decision in cancerNat Rev Cancer20011322223111902577
   PubMed Web of Science ®Google Scholar
• MurphyCGDicklerMNThe role of CDK4/6 inhibition in breast cancerOncologist201520548349025876993
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• RoesleySNASuryadinataRMorrishECyclin-dependent kinase-mediated phosphorylation of breast cancer metastasis suppressor 1 (BRMS1) affects cell migrationCell Cycle201615113715126771717
   PubMed Web of Science ®Google Scholar
• LundbergASWeinbergRAFunctional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexesMol Cell Biol19981827537619447971
   PubMed Web of Science ®Google Scholar
• HarbourJWDeanDCThe Rb/E2F pathway: expanding roles and emerging paradigmsGenes Dev200014192393240911018009
   PubMed Web of Science ®Google Scholar
• EkholmSVReedSIRegulation of G1 cyclin-dependent kinases in the mammalian cell cycleCurr Opin Cell Biol200012667668411063931
   PubMed Web of Science ®Google Scholar
• SherrCJRobertsJMLiving with or without cyclins and cyclin-dependent kinasesGenes Dev200418222699271115545627
   PubMed Web of Science ®Google Scholar
• NursePMasuiYHartwellLUnderstanding the cell cycleNat Med1998410110311069771732
   PubMed Web of Science ®Google Scholar
• CasimiroMCVelasco-VelázquezMAguirre-AlvaradoCPestellRGOverview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and presentExpert Opin Investig Drugs2014233295304
   PubMed Web of Science ®Google Scholar
• LiaoYFengYShenJHornicekFJDuanZThe roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcomaCancer Metastasis Rev2015 Epub 2015 Dec 15
   Web of Science ®Google Scholar
• DukelowTKishanDKhasrawMMurphyCGCDK4/6 inhibitors in breast cancerAnticancer Drugs201526879780626053278
   PubMed Web of Science ®Google Scholar
• KollmannKHellerGSchneckenleithnerCA kinase-independent function of CDK6 links the cell cycle to tumor angiogenesisCancer Cell201324216718123948297
   PubMed Web of Science ®Google Scholar
• ScheicherRHoelbl-KovacicABelluttiFCDK6 as a key regulator of hematopoietic and leukemic stem cell activationBlood201512519010125342715
   PubMed Web of Science ®Google Scholar
• AltenburgJDFaragSSThe potential role of PD0332991 (palbociclib) in the treatment of multiple myelomaExpert Opin Investig Drugs2015242261271
   PubMed Web of Science ®Google Scholar
• PeuralaEKoivunenPHaapasaariK-MBloiguRJukkola-VuorinenAThe prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancerBreast Cancer Res2013151R523336272
   PubMed Web of Science ®Google Scholar
• KonecnyGECyclin-dependent kinase pathways as targets for women’s cancer treatmentCurr Opin Obstet Gynecol2016281424826642065
   PubMed Web of Science ®Google Scholar
• CadooKAGucalpATrainaTAPalbociclib : an evidence-based review of its potential in the treatment of breast cancerBreast Cancer (Dove Med Press)20144612313325177151
   PubMedGoogle Scholar
• TamuraKDevelopment of cell-cycle checkpoint therapy for solid tumorsJpn J Clin Oncol201545121097110226486823
   PubMed Web of Science ®Google Scholar
• TanARYangXBermanAPhase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancerClin Cancer Res200410155038504715297405
   PubMed Web of Science ®Google Scholar
• AsgharUWitkiewiczAKTurnerNCKnudsenESThe history and future of targeting cyclin-dependent kinases in cancer therapyNat Rev Drug Discov201514213014625633797
   PubMed Web of Science ®Google Scholar
• CriscitielloCVialeGEspositoACuriglianoGDinaciclib for the treatment of breast cancerExpert Opin Investig Drugs201423913051312
   PubMed Web of Science ®Google Scholar
• FryDWHarveyPJKellerPRSpecific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol Cancer Ther20043111427143815542782
   PubMed Web of Science ®Google Scholar
• PfizerIBRANCE, FDA drug sheet Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdfAccessed April 23, 2016
   Google Scholar
• RihaniAVandesompeleJSpelemanFVan MaerkenTInhibition of CDK4/6 as a novel therapeutic option for neuroblastomaCancer Cell Int20151517626225123
   PubMed Web of Science ®Google Scholar
• SchröderLBWMcDonaldKLCDK4/6 inhibitor PD0332991 in glioblastoma treatment: does it have a future?Front Oncol2015525926649278
   PubMed Web of Science ®Google Scholar
• LiCQiLBellailACHaoCLiuTPD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axisOncol Lett2014751673167824765199
   PubMed Web of Science ®Google Scholar
• SatheAKoshyNSchmidSCCDK4/6 inhibition controls proliferation of bladder cancer and transcription of RB1J Urol2016195377177926318986
   PubMed Web of Science ®Google Scholar
• HuangSYeHGuoWCDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutationInt J Clin Exp Med201587116921170026380006
   PubMed Web of Science ®Google Scholar
• PerezMMuñoz-GalvánSJiménez-GarcíaMPMarínJJCarneroAEfficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNAOncotarget2015638405574057426528855
   PubMedGoogle Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res2009115R7719874578
   PubMed Web of Science ®Google Scholar
• BoscoEEKnudsenESRB in breast cancer: at the crossroads of tumorigenesis and treatmentCell Cycle20076666767117361100
   PubMed Web of Science ®Google Scholar
• DeanJLThangavelCMcClendonAKReedCAKnudsenESTherapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failureOncogene201029284018403220473330
   PubMed Web of Science ®Google Scholar
• MorikawaAHenryNLPalbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancerClin Cancer Res201521163591359626100274
   PubMed Web of Science ®Google Scholar
• QinGXuFQinTPalbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathwayOncotarget2015639417944180826540629
   PubMed Web of Science ®Google Scholar
• BoccaCIevolellaMAutelliRExpression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasivenessExpert Opin Ther Targets201418212113524325753
   PubMed Web of Science ®Google Scholar
• TaubeJHHerschkowitzJIKomurovKCore epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypesProc Natl Acad Sci U S A201010735154491545420713713
   PubMed Web of Science ®Google Scholar
• AndersLKeNHydbringPA systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cellsCancer Cell201120562063422094256
   PubMed Web of Science ®Google Scholar
• ParrishKEPokornyJMittapalliRKBakkenKSarkariaJNElmquistWFEfflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelJ Pharmacol Exp Ther2015355226427126354993
   PubMed Web of Science ®Google Scholar
• de GooijerMCZhangPThotaNP-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclibInvest New Drugs20153351012101926123925
   PubMed Web of Science ®Google Scholar
• StegerGGGnantMBartschRPalbociclib for the treatment of postmenopausal breast cancer – an updateExpert Opin Pharmacother201617225526326679057
   PubMed Web of Science ®Google Scholar
• SchwartzGKLoRussoPMDicksonMAPhase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1)Br J Cancer2011104121862186821610706
   PubMed Web of Science ®Google Scholar
• FlahertyKTLoRussoPMDeMicheleAPhase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerClin Cancer Res201218256857622090362
   PubMed Web of Science ®Google Scholar
• DeMicheleAClarkASTanKSCDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessmentClin Cancer Res2015215995100125501126
   PubMed Web of Science ®Google Scholar
• VanArsdaleTBoshoffCArndtKTAbrahamRTMolecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatmentClin Cancer Res201521132905291025941111
   PubMed Web of Science ®Google Scholar
• FinnRHurvitzSAllisonMPhase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-NegatiCancer Res20096924 Supplement50695069
   Web of Science ®Google Scholar
• DhillonSPalbociclib: first global approvalDrugs201575554355125792301
   PubMed Web of Science ®Google Scholar
• DicksonMATapWDKeohanMLPhase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaJ Clin Oncol201331162024202823569312
   PubMed Web of Science ®Google Scholar
• TurnerNCRoJAndréFPalbociclib in hormone-receptor-positive advanced breast cancerN Engl J Med2015373320921926030518
   PubMed Web of Science ®Google Scholar
• DeanJLMcClendonAKKnudsenESModification of the DNA damage response by therapeutic CDK4/6 inhibitionJ Biol Chem201228734290752908722733811
   PubMed Web of Science ®Google Scholar
• RobertsPJBisiJEStrumJCMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyJ Natl Cancer Inst2012104647648722302033
   PubMed Web of Science ®Google Scholar
• ClarkASO’DwyerPJHeitjanDA phase I trial of palbociclib and paclitaxel in metastatic breast cancerJ Clin Oncol201432suppl abstr 5275s
   Google Scholar